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INTRODUCTION
-Catenin plays a critical role as a component of the cell-
cell adhesion complex and as a coactivator of the  T-cell tran-
scription factor/lymphoid enhancer binding factor (TCF/LEF)
family of transcription factors (1-5). Inappropriate activation
of this pathway leads to an increase of the level of  -catenin,
which can translocate into the nucleus and up-regulate the
target gene expression and cell proliferation through bind-
ing to the TCF/LEF family members (3-5). It is now appar-
ent that altered expression of  -catenin is an important event
in the genesis of a number of malignancies (6-8).  -Catenin
gene mutation and nuclear accumulation found in hepatocel-
lular carcinoma (HCCs) ranged from 13-34% and 11-43%,
respectively, however, the clinical implication of the aberrant
-catenin expression in HCC remains still unclear (9-16). 
Cyclin D1 is a major regulator of the progression of cells
into the proliferative stage of the cell cycle (17, 18). Recently,
cyclin D1 has been reported as one of the target genes of the
-catenin/TCF pathway; a TCF-binding site was identified
in the promoter region of cyclin D1, and a significant corre-
lation between the expressions of cyclin D1 and  -catenin has
been found in human breast and colon cancers (19-21). Cyclin
D1 gene amplification was reported in less than 15% of HCC
patients (22, 23); however, the frequencies of overexpressions
of cyclin D1 mRNA and cyclin D1 protein were reported in
up to 22% (23) and 58% (24), respectively, in HCC patients.
These results suggest that another mechanism inducing the
overexpression of cyclin D1 mRNA or protein may be present.
In the present study, to evaluate the role of  -catenin in he-
patocarcinogenesis as well as the relationships among the ex-
pressions of  -catenin and cyclin D1, and tumor cell prolif-
eration, we performed an immunohistochemical analysis of
-catenin and cyclin D1 in 77 patients with HCCs, and stud-
ied the relationships between the expressions of  -catenin and
cyclin D1, mitotic index, and other pathologic parameters.
MATERIALS AND METHODS
Patients and Tissue Samples
We retrieved 77 formalin-fixed, paraffin-embedded, sur-
gically resected cases of HCC at Inje University Seoul Paik
Hospital, which were collected from 1997 to 2001. Seventy-
three (94.8%) of the 77 patients were seropositive for HBsAg
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Expression of  -catenin in Hepatocellular Carcinoma in Relation to
Tumor Cell Proliferation and Cyclin D1 Expression
Alteration of  -catenin expression has been implicated in the development of hep-
atocellular carcinoma (HCC). It has been also reported that  -catenin can influence
the tumor cell proliferation or cyclin D1 expression, one of the target factors of  -
catenin. We performed an immunohistochemical analysis of  -catenin and cyclin
D1 in 77 patients with resected HCCs, and examined the relationships between
the expressions of  -catenin and cyclin D1, and other pathologic parameters includ-
ing the mitotic index. Altered expressions of  -catenin including nonnuclear over-
expression and nuclear expression were detected in 58.4% of HCCs (45/77) and
showed significant correlations with large tumor size, poor histologic grade, and
high tumor stage. The mean mitotic index of HCCs with nuclear expression (3.2
±3.0) and nonnuclear overexpression (2.7±2.5) was significantly higher than
that of tumors with no overexpression (1.7±1.4) (p=0.018 and 0.038, respec-
tively), however, no correlation was noted between the expressions of cyclin D1
and  -catenin. In addition, nonnuclear overexpression out of two altered expres-
sion patterns was more frequent (37.7% versus 20.8%) as well as pathologically
more significant than nuclear expression. These results indicate that the altered
expression of  -catenin in HCC may play an important role in tumor progression
by stimulating tumor cell proliferation, and nonnuclear overexpression may have
pathologic significance in HCC.
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and only 4 (5.2%) had serum anti-HCV. Seventy-two patients
were men and 5 were women, and the age of the patients ra-
nged from 35 to 72 yr (mean age, 53 yr). Sixty-seven of the
patients (87%) had a precirrhotic or cirrhotic nontumorous
liver, and the others showed chronic viral hepatitis.
Pathologic Examination
Conventional pathologic parameters were examined. The
histologic grade of tumor differentiation was assigned accord-
ing to the Edmondson and Steiner grading system (25). After
grading, the tumors were classified into 2 groups-well (grade
I+II) (n=37) and poor (grade III+IV) (n=40). The size of the
77 HCCs ranged from 1.0 to 17 cm (mean, 3.7 cm), and the
tumor size was classified based on the criteria of Yumoto et al.
(26) - small (tumor mass <3 cm) (n=32) and large (tumor mass
≥3 cm) (n=45). The tumor staging was performed by using
International Union Against Cancer (UICC, 1997) criteria
(27) - stage 1 (n=7), stage 2 (n=27), stage 3 (n=24), and stage
4 (n=19), respectively.
Immunohistochemical Staining
The conventional avidin-biotin complex (ABC) method was
performed on 4  m-thick sections from each lesion. For anti-
gen retrieval, the sections were immersed in citrate buffer and
processed in a microwave oven at 95℃ for 10 min. Prima-
ry monoclonal antibodies of  -catenin (Clone: 14, Transduc-
tion Laboratories, Lexington, KY) and cyclin D1 (Clone: A-
12, Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) were
used at a 1 to 100 dilution. Sections were immunostained
using the ABC method. 3-Amino-9-ethylcarbazole (AEC) was
used as the chromogen and Meyer’s hematoxylin as a nucle-
us counterstain. Normal saline was used as a substitute for
the primary negative controls. The  -catenin expression pat-
terns were divided into three groups as follows: 1) Nuclear
expression, nuclear staining in more than 20% of the tumor
cells with or without cytoplasmic expression; 2) Nonnuclear
overexpression, increased membranous and/or cytoplasmic
staining with no identifiable nuclear staining in at least 50%
of the tumorous areas; 3) No overexpression, weakly mem-
branous staining similar to that of the adjacent nonneoplas-
tic hepatocytes. We also categorized the cases showing nucle-
ar expression or nonnuclear overexpression as altered expres-
sion and the cases showing no overexpression as normal. For
cyclin D1, only distinct nuclear staining was regarded as pos-
itive. The cyclin D1 labeling index (LI) was defined as the
average of the percentages of cyclin D1-positive cells on 10
randomly selected high power (×400) fields. The mitotic
index was calculated from the numbers of mitotic cells in 10
random high power fields (×400). The mean value of the
mitotic cells counted in each field was defined as the mitot-
ic index. We applied Ki- 67 immunostaining (Clone: 7B11,
Zymed Laboratories, San Francisco, CA, U.S.A.) in selected
cases with the same methods.
Statistical Analysis
The  -catenin expression in relation to the pathologic para-
meters was examined with the  2 test. To analyze the statis-
tical differences of cyclin D1 LI and mitotic index between
groups, the unpaired Student’s t-test or ANOVA was used.
The correlation between cyclin D1 LI and the mitotic index
was analyzed by Pearson’s correlation. Significance was defined
as p<0.05. All statistical analyses were performed using SPSS
software (version 10.0, SPSS INC., Chicago, IL, U.S.A.).
RESULTS
-Catenin Expression
In the nontumorous areas, hepatocytes showed weak to mod-
erate membranous staining with little cytoplasmic expression,
and the bile ductules showed more prominent membranous
expression (Fig. 1A). In the HCCs, altered expression, includ-
ing two distinct patterns of nuclear expression and nonnucle-
ar overexpression, was observed in 45 cases (58.4%). In 16
cases (20.8%) showing nuclear expression, nuclear immuno-
staining was present in 20-60% of neoplastic cells and con-
siderable intracytoplasmic expression was accompanied (Fig.
1B). In 29 cases (27.7%) showing nonnuclear overexpression,
-catenin expression was localized in the cytoplasm, especial-
ly close to the cell membrane, without nuclear expression and
the intensity was obviously stronger than those of nonneoplas-
tic hepatocytes (Fig. 1C, D). No overexpression was observed
in 32 of the 77 HCCs (41.6%), and none of the tumors was
completely negative for  -catenin throughout the tumor.
According to associated viral status, altered expression was
noted in 44 of 73 HBV-associated tumors (60.3%) and one
of 4 HCV-associated tumors (25%).
Tumors with altered expression showed significant corre-
lations with large tumor size (p=0.027), poor histologic grade
(p=0.032), and high tumor stage (p=0.028). Tumors with
nonnuclear overexpression showed a positive correlation with
portal vein invasion (p=0.006) and tumor size (p=0.044), while
nuclear expression showed no correlation with any of patho-
logic parameters examined (Table 1).
Mitotic Index and Cyclin D1 Labeling Index (Table 2)
The average MI in HCCs was 2.4±2.3 (range 0.1-11). The
MI showed a strong correlation with poor histologic grade
(p=0.004), large tumor size (p=0.002), presence of portal vein
invasion (p<0.001), and high tumor stage (p<0.001).
The average cyclin D1 LIs in the nontumorous areas and
HCCs were 13.8 (±13.2; range 1-48) and 26.2 (±18.2; range
1-80), respectively (Fig. 2A, B). There was a positive corre-Expression of  -catenin in Hepatocellular Carcinoma 213
lation between cyclin D1 LIs and tumor size (p=0.02). How-
ever, the cyclin D1 LIs were strikingly variable according to
the histologic differentiation, and the average cyclin D1 LIs
in HCCs with well-differentiated histologic grade (28.3±
17.6) were higher than those in cases with poor histologic
grade (24.3±18.7), although statistically not significant.
Interestingly, we observed fifteen cases of HCC with high
cyclin D1 expression localized in the central portions of the
thick trabeculae or pseudoglandular pattern (Fig. 2C). When
we applied Ki-67 immunostaining in these cases, we found
a noticeable difference between the topologic distribution of
cyclin D1 and Ki-67 stainings (Fig. 2C, D). Furthermore, the
cyclin D1 LIs showed no correlation with the MI (p=0.298,
Pearson’s correlation test).
Relationships of Mitotic Index and Cyclin D1 Labeling
Index with  -Catenin Expression 
According to  -catenin expression patterns (Table 3), the
average MIs (±SD) in cases with nuclear expression, nonnu-
Fig. 1. -catenin immunohistochemical staining. (A) Nonneoplastic hepatocytes showing homogeneous weak membranous staining. The
bile ducts show moderate membranous staining, compared with hepatocytes, (B) HCCs showing strong nuclear and considerable cyto-
plasmic stainings, and (C, D) Low and high magnification photographs of HCCs showing nonnuclear overexpression when compared to
the adjacent nontumorous area. Strong membranous staining with occasional cytoplasmic staining is uniformly distributed throughout the
tumor.
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clear overexpression, and no overexpression were 3.2 (±3.0),
2.7 (±2.5), and 1.7 (±1.4), respectively, and there was a
significant difference between them (p=0.049). HCCs with
nuclear expression and nonnuclear overexpression of  -catenin
showed a significantly higher mitotic index than cases with
no overexpression (p=0.018 and 0.038, respectively). The
average MIs of cases showing nuclear expression were slight-
ly higher than those of cases showing nonnuclear overex-
pression, but there was no statistical significance. No signif-
icant difference was found in the average cyclin D1 LIs accord-
ing to the  -catenin expression patterns.
DISCUSSION
-Catenin plays a fundamental role in the regulation of the
E-cadherin-catenin cell adhesion complex as well as in the Wnt
signaling pathway (1-5). The expression of  -catenin in cells
is controlled by a multiprotein complex, and mutations in the
glycogen synthase kinase 3 (GSK-3 ) phosphorylation sites
of the  -catenin gene (CTNNB1) result in nuclear and/or cyto-
plasmic accumulation of  -catenin and constitutive transac-
tivation of TCF/LEF target genes, a mechanism occurring in
many cancers (3-8). The significances of subcellular localiza-
Fig. 2. Expression of Cyclin D1 protein (A, B, and C) and Ki-67 immunostaining (D). (A) Nonneoplastic hepatocytes showing scattered
cyclin D1-positive nuclei. (B) Well-differentiated HCCs showing high cyclin D1 labeling index, and (C) Localization of cyclin D1-positive
cells to central portion of trabecular or pseudoglandular pattern, discordant to distribution of Ki-67-positive cells (D).
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tion of  -catenin using immunohistochemistry have been re-
ported to be variable according to the tumor types. In colorec-
tal cancer, increased cytoplasmic and nuclear staining seems to
be an independent predictor of poor survival (28), whereas
decrease or loss of expression correlated with poor prognosis
in gastric or pancreatic adenocarcinoma (29, 30). To date, the
reported mutations of  -catenin in HCC involve predominant-
ly GSK-3 phosphorylation sites in exon 3, suggesting inap-
propriate activation of the Wnt signaling pathway, and a high
association between the nuclear  -catenin expression and gene
mutation was previously shown (9-16). 
Most of the previous studies had focused on the nuclear ex-
n=77
Altered expression
present absent
n=45 n=32
p-value
Nonnuclear overexpression
present absent
n=29 n=48
p-value
Nuclear expression
present absent
n=16 n=61
p-value
Etiology of underlying liver disease
HBV (+) 73 44 29 28 45 16 57
HCV (+) 4 1 3 NS 1 3 NS 0 4 NS
Tumor size
Small (<3 cm) 32 14 18 8 24 6 26
Large (≥3 cm) 45 31 14 0.027 21 24 0.044 10 35 NS
Portal vein invasion
Absent 31 14 17 6 25 8 23
Present 46 31 15 NS 23 23 0.006 8 38 NS
Histologic grade
Well 37 17 20 10 27 7 30
Poor 40 28 12 0.032 19 21 NS 9 31 NS
Stage 
T1 7 1 6 1 6 0 7
T2 27 16 11 8 19 8 19
T3 24 13 11 9 15 4 20
T4 19 15 4 0.028 11 8 NS 4 15 NS
Table 1. Relationship between  -catenin expression patterns and pathologic parameters 
HBV: HBsAg positive; HCV: anti-HCV positive; Well: Edmondson-Steiner grade I+II; Poor: Edmondson-Steiner grade III+IV; NS: not significant.
Variables Average mitotic index p-value Average cyclin D1 LI p-value
Tumor size
Small (<3 cm) 1.43±1.82 20.59±15.35
Large (≥3 cm) 3.07±2.37 0.002 30.24±19.07 0.020
Portal vein invasion
Absent 1.06±1.22 27.64±21.67
Present 3.28±2.43 <0.001 25.28±15.53 NS
Histologic grade
Well 1.61±2.16 28.32±17.57
Poor 3.11±2.21 0.004 24.3±18.69 NS
Stage
T1 0.33±0.43 32.86±15.77
T2 1.2±1.19 26.37±22.12
T3 2.43±1.14 26.33±13.80
T4 4.77±2.98 <0.001 23.47±18.25 NS
Table 2. Relationships of mitotic index and cyclin D1 labeling index with pathologic parameters
Well: Edmondson-Steiner grade I+II; Poor: Edmondson-Steiner grade III+IV; NS: not significant.
-catenin expression patterns Average MI p-value Average cyclin D1 LI p-value
No overexpression 1.66±1.37 26.72±14.4
Nuclear expression  3.21±3.03 22.44±22.4
Nonnuclear overexpression 2.74±2.5 27.79±19.6
Table 3. Relationships of mitotic index and cyclin D1 labeling index with  -catenin expression
NS: not significant.
0.018
0.038
NS
NS
NS
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pression pattern of  -catenin (11, 12, 14, 15). There are sev-
eral conflicting reports concerning the association of  -catenin
with tumor progression and patient’ s survival: the results pub-
lished by Hsu et al. (12) and Mao et al. (13) demonstrated
that expression of mutant nuclear  -catenin correlated with
low stage of HCC and favorable prognosis. However, accord-
ing to the results of some recent studies (15, 16), nuclear ex-
pression seems to correlate with tumor progression and poor
prognosis. In our study, altered expressions of  -catenin includ-
ing nonnuclear overexpression and nuclear expression were
detected in 58.4% of HCC and showed significant correla-
tions with large tumor size, poor histologic grade, and high
tumor stage. However, we are not able to find any relation-
ship between nuclear expression of  -catenin and pathologic
features of HCCs. In contrast, nonnuclear overexpression out
of two altered expression patterns was more frequent (37.7%
versus 20.8%) as well as pathologically more significant than
nuclear expression. With regard to proliferative activity, not
only nuclear expression but also nonnuclear overexpression
of  -catenin correlated significantly with high mitotic index.
Nonnuclear overexpression of  -catenin had been previous-
ly mentioned by Endo et al. (31), Nhieu et al. (15), Wong et
al. (11), and Wei et al. (32). Especially, Wong et al. (11) stressed
that the nonnuclear type  -catenin overexpression correlat-
ed significantly with poor prognostic factors in predominant-
ly HBV-associated HCCs as noted in our study, however, they
did not suggest any possible explanation. According to our
results, nonnuclear overexpression of  -catenin appeared to
be a frequent finding in predominantly HBV-associated HCC
and can contribute tumor progression by stimulating tumor
cell proliferation. 
Previous studies have provided evidence that nuclear expres-
sion of  -catenin stimulates tumor cell proliferation or tumor
progression (15), however, little is known about the effect of
cytoplasmic  -catenin. Although molecular mechanism of
nonnuclear overexpression pattern remains elusive, it is pos-
sibly different from that of the nuclear expression pattern due
to the following reasons. First, it is generally accepted that
subcellular distribution of  -catenin regulates its function;
membrane-bound  -catenin predominantly mediates cell-
cell adhesion, whereas elevation of the cytoplasmic and nucle-
ar pool of the protein is associated with an oncogenic func-
tion. Nonnuclear overexpression pattern noted in our study
was mainly membranous staining. Second, in our study, HCCs
with nonnuclear overexpression showed a high association with
portal vein invasion (p=0.006), suggesting that this pheno-
menon might be an effect related to alteration of cell-cell adhe-
sion facilitating vascular invasion. Wei et al. (32) also report-
ed that vascular invasion was frequently noted in HCCs show-
ing enforced expression of the membranous E-cadherin/ -
catenin complex, and they proposed that dynamic up-and
down-regulations of these cell adhesion molecules might be
required for the malignant progression of HCC. Third, most
of the previous studies had focused on the nuclear expression
pattern and showed a high association between the nuclear
expression of  -catenin and HCV-related HCCs (11, 12, 14-
16), whereas HCCs examined in the present study and by
Wong et al. (11) were predominantly HBV-associated, in
which nonnuclear overexpression pattern was predominant
and showed significant correlations with pathologic para-
meters. Although these facts are not sufficient to suggest a
close relationship between nonnuclear overexpression and
HBV-related HCCs, nonnuclear overexpression might be fre-
quently associated with HBV-related HCCs. Further investi-
gation is necessary to resolve this issue.
Although the exact target genes of  -catenin/TCF4 are still
unknown, cyclin D1, one of the major cell cycle regulators, has
been reported as a possible target (19, 20). In our study, we fail-
ed to find an association between the expressions of  -catenin
and the cyclin D1. Considering the reports that overexpression
of an oncogenic form of  -catenin in the liver did not induce
an up-regulation of cyclin D1 in transgenic mice (33), there
might be another pathway or target genes at work in hepato-
carcinogenesis.
Cyclin D1 function is generally presumed to be associated
with cell proliferation. However, contrary to our expectations,
the results in our study showed no correlation between cyclin
D1 expression and the mitotic index as well as different topo-
logic distribution between cyclin D1 and Ki-67 in some cases.
Meanwhile, cyclin D1 LI showed a significant correlation to
large tumor size, which was partially in line with the previous
reports showing that cyclin D1 overexpression exhibits an
advanced clinicopathologic appearance (22, 23). Based on our
results, we could reasonably infer that cyclin D1 expression
may be unrelated to active cell proliferation, and may confer
additional growth advantages to the tumor progression. 
In conclusion, our results indicate that the altered expres-
sion of  -catenin in HCC may play an important role in tumor
progression by stimulating tumor cell proliferation, and non-
nuclear overexpression may have pathologic significance. 
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